ALN-6400 / Alnylam - LARVOL DELTA

HEPATIC PLASMINOGEN LOWERING WITH RNA INTERFERENCE FOR THE TREATMENT OF BLEEDING DISORDERS IS UNLIKELY TO POSE THROMBOTIC RISK BASED ON UK BIOBANK ANALYSES AND MOUSE MODELS OF PROVOKED THROMBOSIS (EHA 2025) - P1 | "Low levels of plasma PLG protein were not associated with thrombosis in UK Biobank analyses, and >99% knockdown of hepatic PLG using a liver-directed siRNA in mouse injury models was not associated with increased thrombus formation. These results suggest that hepatic targeting of PLG with RNAi is unlikely to confer thrombotic risk and support clinical development of ALN-6400, an investigational RNAi therapeutic for the treatment of bleeding disorders (NCT06659640)."

Preclinical • Cardiovascular • Hematological Disorders • Thrombosis • PROS1

Alnylam Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals (Businesswire) - "Zilebesiran – an investigational RNAi therapeutic in development for the treatment of hypertension, in collaboration with Roche. Alnylam expects to: Report results from the KARDIA-3 Phase 2 study in the second half of 2025.Initiate a Phase 3 cardiovascular outcomes trial in the second half of 2025...ALN-6400 – an investigational RNAi therapeutic in development for the treatment of bleeding disorders. Alnylam expects to: Initiate a Phase 2 study in a bleeding disorder in the second half of 2025. In addition, the Company plans to file Investigational New Drug (IND) applications for four new Alnylam-led programs by the end of 2025."

IND • New P2 trial • New P3 trial • P2 data • Cardiovascular • Hematological Disorders • Hypertension